Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

  • Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools for combating hematological diseases confronted with pressing medical needs. Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. Currently, more than 500 CAR-T and 17 CAR-NK cell trials are being conducted worldwide including the four CAR-T cell products Kymriah, Yescarta, Tecartus and Breyanzi, which are already available on the market. Most CAR-T cell-based gene therapy products that are under clinical evaluation consist of autologous enriched T cells, whereas CAR-NK cell-based approaches can be generated from allogeneic donors. Besides modification based on a second-generation CAR, more advanced CAR-immune cell therapeutics are being tested, which utilize precise insertion of genes to circumvent graft-versus-host disease (GvHD) or employ a dual targeting approach and adapter CARs in order to avoid therapy resistance caused by antigen loss. In this review, we are going to take a closer look at the commercial CAR-T cell therapies, as well as on CAR-T and CAR-NK cell products, which are currently under evaluation in clinical trials, that are being conducted in Germany.

Download full text files

Export metadata

Author:Nawid AlbingerORCiD, Jessica HartmannORCiDGND, Evelyn UllrichORCiDGND
Parent Title (English):Gene therapy
Publisher:Nature Publ. Group
Place of publication:London
Document Type:Article
Date of Publication (online):2021/03/22
Date of first Publication:2021/03/22
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2023/10/13
Tag:Cancer; Immunotherapy
Page Number:15
First Page:513
Last Page:527
The laboratory of EU has been supported by the FCI and DKTK (to EU), by the DFG (CRC/SFB 1292 and IRTG; to EU and NA), by the German Cancer Aid (to EU), the “Alfred & Angelika Gutermuth-Stiftung” (to EU), and by “Menschen für Kinder e.V.” (to EU). Open Access funding enabled and organized by Projekt DEAL.
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (German):License LogoCreative Commons - CC BY - Namensnennung 4.0 International